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RESEARCH ARTICLE

CCR2 Signaling Restricts SARS-CoV-2 Infection
Abigail Vanderheiden,a,b,c Jeronay Thomas,d,e Allison L. Soung,f Meredith E. Davis-Gardner,a,b,c Katharine Floyd,a,b,c Fengzhi Jin,b,c,d
David A. Cowan,b,c,h Kathryn Pellegrini,b,c,h Adrian Creanga,l Amarendra Pegu,l Alexandrine Derrien-Colemyn,l Pei-Yong Shi,g
Arash Grakoui,b,c,d Robyn S. Klein,f,i,j Steven E. Bosinger,b,c,h Jacob E. Kohlmeier,d,e Vineet D. Menachery,k Mehul S. Suthara,b,c,e
Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA

a

Emory Vaccine Center, Emory University, Atlanta, Georgia, USA

b
c

Yerkes National Primate Research Center, Atlanta, Georgia, USA
Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA

d

Emory-UGA Center of Excellence of Inﬂuenza Research and Surveillance (CEIRS), Atlanta, Georgia, USA

e

Center for Neuroimmunology and Neuroinfectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

f

Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA

g
h
i

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Department of Neurosciences, Washington University School of Medicine, St. Louis, Missouri, USA

j

k

l

Department of Microbiology and Immunology, Institute for Human Infection and Immunity, World Reference Center for Emerging Viruses and Arboviruses, University of
Texas Medical Branch, Galveston, Texas, USA

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused
a historic pandemic of respiratory disease (coronavirus disease 2019 [COVID-19]), and
current evidence suggests that severe disease is associated with dysregulated immunity
within the respiratory tract. However, the innate immune mechanisms that mediate
protection during COVID-19 are not well deﬁned. Here, we characterize a mouse model
of SARS-CoV-2 infection and ﬁnd that early CCR2 signaling restricts the viral burden in
the lung. We ﬁnd that a recently developed mouse-adapted SARS-CoV-2 (MA-SARSCoV-2) strain as well as the emerging B.1.351 variant trigger an inﬂammatory response
in the lung characterized by the expression of proinﬂammatory cytokines and interferon-stimulated genes. Using intravital antibody labeling, we demonstrate that MASARS-CoV-2 infection leads to increases in circulating monocytes and an inﬂux of
CD451 cells into the lung parenchyma that is dominated by monocyte-derived cells.
Single-cell RNA sequencing (scRNA-Seq) analysis of lung homogenates identiﬁed a
hyperinﬂammatory monocyte proﬁle. We utilize this model to demonstrate that mechanistically, CCR2 signaling promotes the inﬁltration of classical monocytes into the lung
and the expansion of monocyte-derived cells. Parenchymal monocyte-derived cells
appear to play a protective role against MA-SARS-CoV-2, as mice lacking CCR2 showed
higher viral loads in the lungs, increased lung viral dissemination, and elevated inﬂammatory cytokine responses. These studies have identiﬁed a potential CCR2-monocyte
axis that is critical for promoting viral control and restricting inﬂammation within the
respiratory tract during SARS-CoV-2 infection.
IMPORTANCE SARS-CoV-2 has caused a historic pandemic of respiratory disease (COVID-19),

and current evidence suggests that severe disease is associated with dysregulated immunity
within the respiratory tract. However, the innate immune mechanisms that mediate protection during COVID-19 are not well deﬁned. Here, we characterize a mouse model of SARSCoV-2 infection and ﬁnd that early CCR2-dependent inﬁltration of monocytes restricts
the viral burden in the lung. We ﬁnd that SARS-CoV-2 triggers an inﬂammatory response in
the lung characterized by the expression of proinﬂammatory cytokines and interferon-stimulated genes. Using RNA sequencing and ﬂow cytometry approaches, we demonstrate that
SARS-CoV-2 infection leads to increases in circulating monocytes and an inﬂux of CD451
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cells into the lung parenchyma that is dominated by monocyte-derived cells. Mechanistically,
CCR2 signaling promoted the inﬁltration of classical monocytes into the lung and the expansion of monocyte-derived cells. Parenchymal monocyte-derived cells appear to play a protective role against MA-SARS-CoV-2, as mice lacking CCR2 showed higher viral loads in the
lungs, increased lung viral dissemination, and elevated inﬂammatory cytokine responses.
These studies have identiﬁed that the CCR2 pathway is critical for promoting viral control
and restricting inﬂammation within the respiratory tract during SARS-CoV-2 infection.
KEYWORDS lung inﬂammation, monocytes, SARS-CoV-2, innate immunity, mouse model

S

RESULTS
Variant B.1.351 and MA-SARS-CoV-2 replicate in the lungs of C57BL/6 mice. To
investigate the immunological response to SARS-CoV-2 in the lung, we generated an
MA-SARS-CoV-2 strain (see Fig. S1A in the supplemental material). We engineered
mutations into the infectious clone (ic) SARS-CoV-2 backbone (14) that have been
shown to increase SARS-CoV-2 virulence in mice (15). Next, this virus was serially passaged 20 times in the lungs of BALB/c mice. Deep sequencing of plaque-isolated virus
revealed three additional acquired mutations, which include two within the spike
(K417N and H655Y) and one within the envelope (E8V) gene. Next, we conﬁrmed the
utility of MA-SARS-CoV-2 as a model to study SARS-CoV-2 pathogenesis in C57BL/6
mice. Intranasally infected mice survived infection with MA-SARS-CoV-2 but had 10%
body weight loss at days 2 to 3 postinfection (p.i.) (Fig. 1A). Lung tissue was harvested
at 0, 2, and 4 days p.i., and infectious MA-SARS-CoV-2 was measured via a plaque assay.
MA-SARS-CoV-2 titers peaked at day 2 p.i., with 109 PFU per g of lung tissue. Viral RNA
peaked in the lung at day 2 p.i., dropping 100-fold by day 4 p.i. (Fig. 1B). To determine
the localization of MA-SARS-CoV-2 in the lung, we performed in situ hybridization (ISH)
using probes that target the spike gene of SARS-CoV-2. Viral RNA was restricted to cells
lining the airways of the lung, in accordance with observations in humans (Fig. 1C)
(16). Examination of the antiviral response to MA-SARS-CoV-2 in the lung found that
the expression of Ifnl2 and interferon-stimulated genes (ISGs) peaked at day 2 p.i.
Chemokines (Cxcl10, Ccl2, and Ccl5) and endogenous pyrogens (Il6, Tnf, and Il1b) were
upregulated in response to MA-SARS-CoV-2 infection in the lung (Fig. S1B). We next
plotted the gene expression of representative transcripts against viral RNA and found
November/December 2021 Volume 12 Issue 6 e02749-21
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evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that emerged in Wuhan, China, in December 2019 and is the causative
agent of coronavirus disease 2019 (COVID-19) (1, 2). Innate immunity to SARS-CoV-2
begins with a limited interferon (IFN) response and the production of inﬂammatory
cytokines (interleukin-6 [IL-6], IL-1 b , tumor necrosis factor alpha [TNF-a], and IL-8) by
respiratory epithelial cells or alveolar macrophages (3–7). As shown in bronchoalveolar
lavage (BAL) ﬂuids of COVID-19 patients, this innate immune response coincides with
robust inﬁltration of neutrophils, monocytes, and dendritic cells (DCs) into the lung airways (6, 8). Monocytes in the lung parenchyma can be divided into subpopulations
characterized by their expression of Ly6C: Ly6C-high classical monocytes are proinﬂammatory, whereas Ly6C-low nonclassical monocytes promote wound healing (9, 10).
Ly6C-low monocytes are prevalent under homeostatic conditions; however, after viral
infection, Ly6C-high monocytes will inﬁltrate the lung in a CCR2-dependent manner
(10–12). Classical Ly6C-high monocytes can differentiate into monocyte-derived dendritic cells (moDCs), which increase in number in response to viral respiratory infection,
produce type I IFN, and excel at antigen presentation (13). The contribution of monocytes to the promotion of protective immunity to SARS-CoV-2 infection is not known.
In this study, we utilize a mouse-adapted SARS-CoV-2 (MA-SARS-CoV-2) strain and the
human variant B.1.351 to evaluate the contribution of monocytes to protective immunity against SARS-CoV-2 and identify a CCR2-monocyte axis that is critical for promoting viral control and restricting inﬂammation within the respiratory tract during SARSCoV-2 infection.

®

FIG 1 MA-SARS-CoV-2 and B.1.351 replicate in the respiratory tract. C57BL/6J mice were infected intranasally with 5  105 PFU of MA-SARS-CoV-2 or an
equal volume of PBS for mock mice. (A) Percentage of initial weight for mock- and MA-SARS-CoV-2-infected mice over 8 days. (B) Quantiﬁcation of MASARS-CoV-2 titers from lung tissue at the indicated day postinfection as measured by a plaque assay (left) or qRT-PCR (right). Threshold cycle (CT) values
are represented as relative fold changes over mock (log10). (C) In situ hybridization was performed using a probe for MA-SARS-CoV-2 spike protein RNA.
Representative images of lung slices from mock or day 4 p.i. are shown. (D) The fold change over mock for the indicated gene was plotted against the
corresponding MA-SARS-CoV-2 RNA for each sample, and linear regression was used to determine correlation. (E) Quantiﬁcation of viral titers from lung
tissue by a plaque assay at day 2 p.i. from mice infected with MA-SARS-CoV-2 or human variant B.1.351 (5  105 PFU/mouse). On the right is the
quantiﬁcation of the RNA-dependent RNA polymerase (RdRp) fold change over mock. (F) Gene expression measured via qRT-PCR for the indicated genes
from lungs infected with MA-SARS-CoV-2 or B.1.351 at 2 days p.i. Results are representative of data from 2 independent experiments with 5 mice per
group. Statistical signiﬁcance was determined using unpaired Student’s t tests or linear regression. *, P , 0.05; ****, P , 0.0001.

that Iﬁh1, Ifnl2, and Il6 levels positively correlated with the MA-SARS-CoV-2 viral burden
(Fig. 1D). Thus, MA-SARS-CoV-2 infects the respiratory tract and induces a viral load-dependent inﬂammatory response in C57BL/6 mice.
MA-SARS-CoV-2 contains several mutations, including three within the spike protein, at residues K417N and N501Y, which also appear in the SARS-CoV-2 B.1.351 variant (17). Next, we evaluated if a natural clinical isolate of B.1.351 could establish infection in mice. We intranasally inoculated C57BL/6 mice with 5  105 PFU of B.1.351 or
MA-SARS-CoV-2 and found that B.1.351 replicated to high viral titers within lungs, as
measured by plaque assays and quantitative reverse transcription-PCR (qRT-PCR) for
RNA-dependent RNA polymerase (RdRp) RNA (Fig. 1E). The B.1.351 variant induced levels of cytokine and ISG expression similar to those induced by MA-SARS-CoV-2 in the
lung at day 2 p.i. (Fig. 1F). Combined, these data demonstrate that the variant B.1.351
can infect C57BL/6 mice and replicates similarly to MA-SARS-CoV-2.
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MA-SARS-CoV-2 infection induces hyperinﬂammatory monocytes and dysregulated
alveolar macrophages. To investigate cellular innate immunity to SARS-CoV-2, we performed single-cell RNA sequencing (scRNA-Seq) on lung homogenates from day 0 or 4
after infection with MA-SARS-CoV-2 (4 mice per group). We obtained 9,399 cells at day
0 and 10,982 cells at day 4 p.i., and unbiased clustering identiﬁed 23 distinct groups
comprised of T cells, B cells, DCs, epithelial (Epi) cells, neutrophils (Neut), natural killer
(NK) cells, alveolar macrophages (AMs), and monocytes (mono). We further distinguished between inﬂammatory (Inﬂ), nonclassical (NC), and intermediate (Tr) monocytes (Fig. 2A). MA-SARS-CoV-2 induced a decrease in the frequency of epithelial cells
and increases in the frequencies of inﬂammatory monocytes and DCs in the lung
(Fig. 2B).
We next mapped the expression of genes previously associated with COVID-19 progression to cell subsets in our MA-SARS-CoV-2 model (Fig. 2C). We noted low and sporadic expression levels of Ifnb1 or Ifnl2 but pronounced ISG expression, Isg15 and Irf7,
in alveolar macrophage, monocyte, and DC populations. Inﬂammatory cytokines were
expressed primarily in neutrophils (Il1b) or monocytes (Cxcl16). Other markers associated with COVID-19 were also localized to neutrophil (S100a8) or monocyte (Mmp14)
populations (Fig. 2C) (18). While the chemokine Ccl2 was expressed primarily by inﬂammatory monocytes, the cognate receptor, Ccr2, was more widespread, with expression
on monocytes, DCs, and NK cells (Fig. 2C). Gene set enrichment analysis (GSEA) of
inﬂammatory monocyte populations identiﬁed an enrichment of inﬂammatory, interferon alpha, and interferon gamma response genes after MA-SARS-CoV-2 infection
(Fig. 2D). Thus, MA-SARS-CoV-2 results in a proinﬂammatory response driven by neutrophils and inﬂammatory monocytes.
Alveolar macrophages showed changes in frequency after MA-SARS-CoV-2 infection
(Fig. 2B). To further examine this population, we performed a heat map analysis of the
top differentially expressed genes (DEGs) between mock- and MA-SARS-CoV-2-infected
samples. MA-SARS-CoV-2 infection upregulated genes involved in antigen presentation
(B2m and H2-q7), ISGs (Iﬁ2712a and Oas1a), and inﬂammatory cytokines (Ccl9 and Ccl6)
(Fig. 2E). We performed GSEA using a gene list enriched in alveolar macrophages from
COVID-19 patients and found that alveolar macrophages from MA-SARS-CoV-2infected mice had both a hyperinﬂammatory and suppressive signature (Fig. 2F) (6).
Together, these data demonstrate that alveolar macrophages adopt a dysregulated
proﬁle in MA-SARS-CoV-2-infected mice.
Monocytes and monocyte-derived cells rapidly inﬁltrate the lung in response to
MA-SARS-CoV-2 infection. Next, we investigated the cellular innate immune response
to MA-SARS-CoV-2 at days 0, 2, and 4 p.i. Mice were intravitally labeled with CD45 conjugated to phycoerythrin (PE) to allow the identiﬁcation of circulating (CD451 in vivo)
and parenchymal (CD452 in vivo) cells in the lung. MA-SARS-CoV-2 infection initiated a
stepwise increase in the total circulating and parenchymal CD451 cell inﬁltrate in the
lung at days 2 and 4 p.i. (Fig. 3A; see Fig. S2 for the gating strategy). Granulocyte numbers were elevated in circulation at 2 and 4 days p.i. and inﬁltrated into the lung by
day 2 p.i., with a 100-fold increase in parenchymal neutrophils (Fig. 3B; Fig. S3A).
Circulating macrophage numbers were unchanged by infection; however, beginning
at day 2 p.i., parenchymal macrophage numbers decreased compared to those in
mock-infected mice (Fig. 3C). This downward trend appeared to be due to a sequential
loss of alveolar macrophages at days 2 and 4 p.i. (Siglec-F1 CD11c1), while interstitial
macrophages (CD11c2 Siglec-F2 Ly6C2) were unaffected (Fig. 3D). At day 4 p.i., we
observed a 100-fold increase in cells that expressed both macrophage markers, CD64
and F4/80, and monocyte markers, Ly6C and CD11b, which we designated “transitional
macrophages” (Fig. 3D). All macrophages upregulated major histocompatibility complex class I (MHC-I) in response to MA-SARS-CoV-2, although the effect was more pronounced in transitional macrophages, which also upregulated CD86 (Fig. S3B and C).
Together, these data identify a shift in the lung macrophage composition, with
decreased numbers of alveolar macrophages and increased numbers of activated transitional macrophages during MA-SARS-CoV-2 infection.
November/December 2021 Volume 12 Issue 6 e02749-21
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FIG 2 MA-SARS-CoV-2 induces hyperinﬂammatory monocytes and macrophages in the lung. C57BL/6 mice were infected with MA-SARS-CoV-2, and
lungs were harvested at days 0 and 4 p.i., processed to a single-cell suspension, captured in droplets on a 10 chromium controller, and analyzed via

(Continued on next page)
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FIG 3 Monocytes and monocyte-derived cells rapidly inﬁltrate the lung parenchyma in response to MA-SARS-CoV-2 infection. C57BL/6 mice were infected
with MA-SARS-CoV-2, and lung tissue was harvested at 0, 2, and 4 days p.i. and analyzed via ﬂow cytometry. (A) Five minutes prior to euthanization, mice
were intravitally labeled with CD45:PE. Representative gating of in vivo-labeled CD451 cells used to identify lung circulating (CD451 in vivo) or lung
parenchymal (CD452 in vivo) cells is shown. The total number of CD451 ex vivo cells is quantiﬁed on the right. (B) Counts of neutrophils (lineage negative
CD11b1 Ly6G1) over the course of infection. (C) Counts of macrophages at days 0, 2, and 4 p.i. (lineage negative Ly6G2 CD641 F4/801). (D) Representative
ﬂow gating for alveolar (Siglec-F1 CD11c1), interstitial (Siglec-F2 CD11c2 Ly6C2), or transitional (Siglec-F2 CD11c2 Ly6C1) macrophages from day 4 p.i.
Quantiﬁed on the right are the counts of each population. (E) Quantiﬁcation of cDCs (lineage negative Ly6G2 CD642 MHC-II1 CD11c1 CD261) or moDCs
(lineage negative Ly6G2 MHC-II1 CD11b1 CD11c1) at the indicated time points. (F) Total monocyte (lineage negative Ly6G2 MHC-II2 CD11c2 CD64 low)
counts for circulating or lung parenchymal cells at days 0, 2, and 4 p.i. (G) Representative gating strategy demonstrating forward-scatter height (FSC-H)
against Ly6C to identify different monocyte subsets (Ly6C high, Ly6C intermediate [Int], and Ly6C low), with quantiﬁcation on the right. Results are
representative of data from two independent experiments with 5 mice per group. Statistical signiﬁcance was determined using unpaired one- or two-way
ANOVA. *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001.

We next examined the role of dendritic cells during MA-SARS-CoV-2 infection.
Plasmacytoid dendritic cell (pDC) numbers did not change in the circulation or parenchyma at 2 to 4 days p.i. (Fig. S3D). Conventional dendritic cell (cDC) populations
remained steady in circulation but increased 10-fold in the lung parenchyma at day 4 p.i.,
FIG 2 Legend (Continued)
scRNA-Seq (n = 4 per group). (A) UMAP plot illustrating the different cellular subsets identiﬁed in the lung. (B) UMAP distribution of cells from mock- or
MA-SARS-CoV-2-infected mice. On the right is the frequency of mock versus infected cells that make up each subset deﬁned by UMAP analysis. (C) Feature
plots displaying average expression in normalized read count (NRC) of the indicated gene from mock and infected lungs. (D) GSEA of inﬂammatory
monocytes using the hallmark database from MSigDB for the indicated gene set. (E) Heat map analysis of top-scoring DEGs in alveolar macrophages from
mock- or SARS-CoV-2-infected lungs. (F) GSEA plots of the indicated gene set from Liao et al. (6) in alveolar macrophages from mock and infected lungs.
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which was primarily due to an increase in cDC type 2 cells (cDC2s) (Fig. 3E; Fig. S3E). Lung
parenchymal cDCs increased the expression of MHC-I and CD86 in response to MA-SARSCoV-2 at day 4 p.i. (Fig. S3F). moDCs had slightly increased numbers in circulation and a
10-fold increase in lung parenchymal populations at day 4 p.i. (Fig. 3E). Parenchymal
moDCs also upregulated the expression of MHC-I and CD86 at day 4 p.i. compared to
uninfected controls (Fig. S3G). Thus, cDCs and moDCs undergo expansion and activation
in response to MA-SARS-CoV-2 infection in the lung.
Investigation of monocyte dynamics during MA-SARS-CoV-2 infection showed a 5-fold
increase in circulating monocytes and a 20-fold increase in lung parenchymal monocytes
by day 2 p.i. that remained high through day 4 p.i. (Fig. 3F). Ly6C-high monocytes drove
monocytic inﬁltration into the lung, as their numbers increased 100-fold at days 2 and 4
p.i., but the numbers of Ly6C-low monocytes remained constant (Fig. 3G). All lung parenchymal monocytes showed increased expression of MHC-I at day 4 p.i. (Fig. S3H). Ly6Chigh monocytes had particularly elevated expression of CD86 (2,000% increase) at day 4
p.i. compared to mock (Fig. S3I). Analysis of splenic immunity found that neutrophils had
signiﬁcantly increased numbers at day 4 p.i. (Fig. S4A). Dendritic cells showed increased
expression of MHC-I at 4 days p.i. (Fig. S4B). Together, these data show that MA-SARSCoV-2 infection prompts systemic immune activation and a lung parenchymal immune
response dominated by the inﬁltration of activated monocytes and monocyte-derived cells.
Expansion of monocyte-derived cells in the lung parenchyma during MA-SARSCoV-2 infection is CCR2 dependent. Classical Ly6C-high monocytes migrate to the lung
parenchyma in a CCR2-dependent manner and can differentiate into interstitial macrophages or moDCs (11, 19). Additionally, we observed high expression levels of CCR2
ligands (Ccl2) (Fig. 1F and Fig. 2C) and CCR2 on lung-inﬁltrating monocytes (Fig. 2C).
Therefore, we next evaluated the contribution of CCR2 signaling to the recruitment of
monocytes to the lung during MA-SARS-CoV-2 infection. Flow cytometry analysis of lungs
at day 4 p.i. found similar circulating monocyte numbers but a 2-fold drop in the number
of lung parenchyma-inﬁltrating monocytes in Ccr22/2 mice compared to the wild type
(WT) (Fig. 4A). This decrease appeared to be driven by a 4-fold drop in Ly6C-high and
Ly6C-intermediate monocytes in the lungs of Ccr22/2 mice (Fig. 4B). Circulating moDC
numbers were unaltered by the absence of CCR2, but lung parenchymal moDCs dropped
10-fold in Ccr22/2 mice at day 4 p.i. (Fig. 4C). cDC numbers in circulation were similar
between WT and Ccr22/2 mice at day 4 p.i., but lung parenchymal cDC numbers at day 4
p.i. were 5-fold lower than those of the WT (Fig. 4D). This was due to a speciﬁc loss of
cDC2s (Fig. 4D). All monocyte subsets showed decreased expression of CD86 (2-fold
decrease) at day 4 p.i. in Ccr22/2 mice, while MHC-I levels were decreased only in the
Ly6C-intermediate subset (Fig. 4E). The expression of antigen presentation markers on
moDCs was unchanged by CCR2 (Fig. S5A). Lung-inﬁltrating cDC2s from Ccr22/2 mice had
lower expression levels of MHC-I, but not CD86, than WT cells at 4 days p.i. (Fig. S5B).
Together, these data show that CCR2 signaling promotes the inﬁltration of activated
Ly6C-high and -intermediate monocytes, moDCs, and cDC2s into the lung parenchyma
during MA-SARS-CoV-2 infection.
We investigated if CCR2-low/negative innate immune cells (Fig. 3C) were impacted by
secondary effects of CCR2. The total number of macrophages in circulation or in the lung
parenchyma was not affected by CCR2 4 days after infection with MA-SARS-CoV-2
(Fig. 4F). Alveolar and interstitial macrophages were not impacted by CCR2 signaling.
However, Ccr22/2 mice had a 10-fold drop in transitional macrophage numbers compared to WT mice (Fig. 4G). The expression of CD86 and MHC-I was also decreased on
transitional macrophages from Ccr22/2 mice at day 4 p.i. Despite similar numbers in WT
and Ccr22/2 mice, interstitial macrophages failed to upregulate the expression of both
MHC-I and CD86 in Ccr22/2 mice at day 4 p.i. The mean ﬂuorescence intensity (MFI) of
the expression of CD86 on alveolar macrophages from Ccr22/2 mice was modestly
decreased compared to the WT (Fig. 4H). Thus, the activation of macrophages and expansion of transitional macrophages are CCR2 dependent during MA-SARS-CoV-2 infection.
Lung parenchymal granulocyte numbers were not signiﬁcantly altered between WT
and Ccr22/2 mice at day 4 p.i. (Fig. S5C). However, there was a modest increase in the
November/December 2021 Volume 12 Issue 6 e02749-21
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FIG 4 Expansion of monocyte-derived cells in the lung during MA-SARS-CoV-2 infection is CCR2 dependent. C57BL/6 and Ccr22/2 mice were infected with
MA-SARS-CoV-2, and lung tissue was harvested at 0 and 4 days p.i. and analyzed via ﬂow cytometry. Circulating (Circ.) versus parenchymal (Par.) cells were
distinguished as described in the legend of Fig. 2. (A) Number of total monocytes in the lung circulation or parenchyma. (B) Representative gating
identifying Ly6C-high, -intermediate (Int), or -low monocytes from WT and Ccr22/2 lung parenchyma. Counts for each subset are quantiﬁed to the right. (C)
Quantiﬁcation of moDCs at day 4 p.i. (D) Total numbers of cDCs and parenchymal cDC subsets (right). (E) MFIs for CD86 (left) and MHC-I (right) expression
on monocyte subsets from the lung parenchyma. (F) Quantiﬁcation of the total macrophage numbers at day 4 p.i. (G) Representative ﬂow plots illustrating
interstitial or transitional macrophage populations from WT and Ccr22/2 lung-inﬁltrating cells. Counts of macrophage subsets are quantiﬁed on the right.
(H) Representative histograms of the MFIs for CD86 (left) and MHC-I (right) for each macrophage subset at 4 days p.i. from WT, Ccr22/2, or WT mock lunginﬁltrating cells. Results are representative of data from two independent experiments with 5 mice per group. Statistical signiﬁcance was determined using
unpaired one- or two-way ANOVA. *, P , 0.05; **, P , 0.01; ***, P , 0.001; ****, P , 0.0001.

number of granulocytes in circulation and the spleen from Ccr22/2 mice compared to
WT mice at day 4 p.i. (Fig. S5C and D). Total splenic macrophage numbers were also
higher in the absence of CCR2 at day 4 p.i. (Fig. S5D). Monocyte, moDC, and pDC populations in the spleen were unaffected by CCR2; however, numbers of cDCs in the
spleen were increased in Ccr22/2 mice at day 4 p.i. compared to the WT (Fig. S5D).
These data identify a role for CCR2 in promoting the inﬁltration of activated, Ly6C-high
monocytes and monocyte-derived cells to the lung during MA-SARS-CoV-2 infection.
CCR2 signaling restricts SARS-CoV-2 in the lung. To determine if CCR2 was protective against MA-SARS-CoV-2, we infected WT or Ccr22/2 mice with MA-SARS-CoV-2
and assessed the viral burden at day 4 p.i. Ccr22/2 mice had a 10-fold-higher viral burden in lung tissue as measured by a plaque assay or qRT-PCR (Fig. 5A and B). At day 4
p.i., Ifnl2, cytokines (Il6), and chemokines (Cxcl10 and Ccl2) were elevated in Ccr22/2
compared to WT lungs (Fig. 5C). In situ hybridization showed that Ccr22/2 lungs had
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FIG 5 CCR2 restricts MA-SARS-CoV-2 burden and inﬂammatory cytokines in the lung. C57BL/6 or Ccr22/2 mice were infected with MA-SARS-CoV-2, and
lung tissue was collected at day 4 p.i. (A) Infectious virus at day 4 p.i. as quantiﬁed via plaque assays. (B) qRT-PCR for SARS-CoV-2 RdRp. (C) qRT-PCR was
performed to probe for the indicated IFN signaling (left) or inﬂammatory (right) transcripts. (D) Representative images of in situ hybridization to visualize
MA-SARS-CoV-2 RNA in lung tissue slices from 0 and 4 days p.i. in both WT and Ccr22/2 mice. (E) WT or Ccr22/2 mice were infected with B.1.351, and lungs
were harvested at day 4 p.i. Virus was quantiﬁed via a plaque assay (top) or qRT-PCR (bottom). (F) WT and Ccr22/2 mice were monitored over 12 days after
infection with B.1.351 for survival (top) and weight loss (bottom). Results are representative of data from two independent experiments with 5 mice per
group. Statistical signiﬁcance was determined using unpaired Student’s t test, one-way ANOVA, or Kaplan-Meier survival curve analysis. *, P , 0.05; **, P , 0.01;
***, P , 0.001; ****, P , 0.0001.

November/December 2021 Volume 12 Issue 6 e02749-21

mbio.asm.org 9

Downloaded from https://journals.asm.org/journal/mbio on 11 May 2022 by 128.252.212.229.

CCR2 Restricts SARS-CoV-2 Infection

®

Vanderheiden et al.

DISCUSSION
SARS-CoV-2 infection in humans has identiﬁed a robust and reproducible correlation
between inﬂammatory cytokine levels and disease severity during COVID-19 (6). In accordance, we found that SARS-CoV-2-infected mice had a proinﬂammatory cytokine proﬁle in the lung containing pyrogens (Il6 and Tnf), chemoattractants for monocytes (Ccl2)
and T cells (Cxcl10), ISGs (Irf7 and Isg15), alarmins (S100a8), and matrix metalloproteinases
(Mmp14) (6, 20–23). Interestingly, inﬂammatory gene expression in the lung was MASARS-CoV-2 viral load dependent, as most cytokine transcripts surveyed by quantitative
PCR (qPCR) positively correlated with viral RNA. Similar phenomena have been noted in
human subjects, with one study describing an association between SARS-CoV-2 burden,
IL-6 levels, and an increased risk of death (24). Similar to studies of postmortem lung tissue or BAL ﬂuids from patients suffering from COVID-19, we observed a signiﬁcant
increase in the numbers of S100a81 granulocytes in the lung parenchyma (4, 6–8).
S100a8/9 and Toll-like receptor 4 (TLR4) signaling mediate the emergence of a dysregulated neutrophil population that promotes SARS-CoV-2 disease (18). Neutrophil and
inﬂammatory cytokine levels were higher in Ccr22/2 mice, likely driven by the increased
viral burden in Ccr22/2 lungs. Thus, the MA-SARS-CoV-2 burden is likely directly driving
cytokine expression and neutrophilic inﬁltration into the lung.
CCR2 expression is a deﬁning feature of inﬂammatory Ly6C-high blood monocytes
(9). In various models of respiratory disease, including inﬂuenza, Mycobacterium tuberculosis, and allergic inﬂammation, deletion of Ccr2 negates the ability of monocytes to
enter the lung parenchyma (11, 25, 26). Similarly, we found that CCR2 had no effect on
circulating monocyte numbers but speciﬁcally promoted the inﬁltration of activated
monocytes into the lung parenchyma during SARS-CoV-2 infection. However, unlike in
inﬂuenza, Ccr22/2 mice still had a signiﬁcant increase in lung-inﬁltrating Ly6C-high
monocytes compared to mock, suggesting that CCR2 signaling may be partially redundant during SARS-CoV-2 infection (11). Inﬂammatory monocytes express a variety of
chemokine receptors, including CXCR3, whose ligand (CXCL10) is elevated in Ccr22/2
mice and could compensate for the loss of CCR2. Monocyte-derived interstitial macrophages and moDCs also depended on CCR2 for expansion in the lung parenchyma
(27). In contrast, alveolar macrophages, which are self-renewing and primarily fetus
derived, were unaffected by the absence of CCR2 (28–30). Previous studies in a model
of sterile lung inﬂammation demonstrated that DC precursors required CCR2 for entry
into the lung, and accordingly, in MA-SARS-CoV-2 infection, cDC2 lung parenchymal
populations were also decreased in the absence of CCR2 (31). These data suggest that
CCR2 plays an essential and speciﬁc role in promoting the recruitment and differentiation of monocytes into transitional macrophage and moDC populations during MASARS-CoV-2 infection. In this study, we focused on the role of monocyte-derived cells;
however, CCR2 is expressed on other cell populations, including NK cells and T cells.
Exploration of CCR2 signaling on other cell types at early and late time points will be
an important topic for future studies to explore the role of CCR2 signaling in both
innate and adaptive responses.
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more robust detection of viral RNA than WT mice. Additionally, while viral RNA was
localized to cells lining the airway spaces in WT mice, Ccr22/2 lungs had inﬁltration of
viral RNA further into the interstitial and parenchymal spaces (Fig. 5D). Next, we investigated if CCR2 restricted B.1.351 infection. Ccr22/2 mice had a signiﬁcantly higher viral
burden in the lung at day 4 p.i. than did WT mice, as assessed by a plaque assay or
qRT-PCR (Fig. 5E). To determine the impact of a higher viral burden on SARS-CoV-2
infection outcomes, we performed a survival study of WT and Ccr22/2 mice using
B.1.351. Ccr22/2 mice lost 10% more weight than their WT counterparts. While infection with B.1.351 did not cause mortality in WT mice, B.1.351 infection resulted in 60%
mortality in Ccr22/2 mice (Fig. 5F). Together, these data show that CCR2-mediated signaling and immune cell recruitment restrict inﬂammation, viral burden, and viral dissemination in the lung to provide protection against SARS-CoV-2 infection.
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In contrast to other respiratory infections such as inﬂuenza, in which CCR2 promotes
mortality and inﬂammation, our study found that CCR2 restricted viral burden and weight
loss during MA-SARS-CoV-2 infection (11). CCR2 promoted the inﬁltration of monocytederived cells into the lung parenchyma, and while we did not directly assess the role of
monocytes in restricting virus, this suggests an essential role for Ly6C-high monocytes,
moDCs, and transitional macrophages in controlling SARS-CoV-2 infection. Macrophages
were previously shown to control viruses through the secretion of inducible nitric oxide
synthase (iNOS) and the phagocytosis of viral particles, while moDCs play a key role in
type I IFN release and priming the T cell response (13, 32). Further studies are needed to
delineate the precise mechanisms that these cell subsets use to control SARS-CoV-2.
Current evidence in the ﬁeld of SARS-CoV-2 research suggests that a large portion of the
pathology of COVID-19 is due to a monocyte-driven cytokine storm (33). Here, we identify
data that suggest that monocyte-derived cells in the lung are crucial for limiting viral burden and cytokine production during the early stages of MA-SARS-CoV-2 infection. Most
studies to date of the immune response in humans have focused on late time points of
infection; therefore, monocytes could be protective early and pathological later during
infection resolution. The consideration of the role of monocyte-derived cells in restricting
SARS-CoV-2 infection in the lung and priming adaptive immune responses will be essential for the design of future therapies and vaccines.

Viruses and cells. VeroE6 cells were obtained from the ATCC (clone E6; ATCC CRL-1586) and cultured
in complete Dulbecco’s modiﬁed Eagle’s medium (DMEM) consisting of 1 DMEM (catalog number 45000304; VWR), 10% fetal bovine serum (FBS), 25 mM HEPES buffer (Corning Cellgro), 2 mM L-glutamine, 1 mM
sodium pyruvate, 1 nonessential amino acids, and 1 antibiotics. VeroE6-TMPRSS2-hACE2 cells were
kindly provided by Barney Graham (Vaccine Research Center, NIH, Bethesda, MD). The generation of MASARS-CoV-2 will be described in a future publication. In brief, MA-SARS-CoV-2 was generated by engineering four coding mutations (NSP6 L37F, NSP10 P87S, S N501Y, and N D128Y) into the backbone of
icSARS-CoV-2 (WA/1 backbone). This virus was then passaged 20 times in BALB/c mice, followed by deep
sequencing, which identiﬁed 3 additional acquired mutations (S T417N, S H655Y, and E E8V). This virus,
termed MA-SARS-CoV-2, was passaged once in VeroE6 cells to generate a working stock. The B.1.351 variant was provided by Andy Pekosz (John Hopkins University, Baltimore, MD). Viral stocks were grown on
VeroE6 cells, and viral titers were determined by plaque assays on VeroE6 cells or VeroE6-TMPRSS2hACE2 cells (ATCC). Vero cells were cultured in complete DMEM consisting of 1 DMEM (Corning
Cellgro), 10% FBS, 25 mM HEPES buffer (Corning Cellgro), 2 mM L-glutamine, 1 mM sodium pyruvate, 1
nonessential amino acids, and 1 antibiotics. VeroE6-TMPRSS2-hACE2 cells were cultured in complete
DMEM in the presence of puromycin at 10 mg/ml (catalog number A11138-03; Gibco).
Infection of mice with MA-SARS-CoV-2. C57BL/6J and Ccr22/2 mice were purchased from Jackson
Laboratories or bred in-house at the Yerkes National Primate Research Center rodent facility at Emory
University. All mice used in these experiments were females between 8 and 12 weeks of age. Stock MASARS-CoV-2 or B.1.351 virus was diluted in phosphate-buffered saline (PBS) to a working concentration
of 1  107 PFU/ml. Mice were anesthetized with isoﬂurane and infected intranasally with virus (50 m l;
5  105 PFU/mouse) in an animal biosafety level 3 (ABSL-3) facility. Mice were monitored daily for weight
loss. All experiments adhered to the guidelines approved by the Emory University Institutional Animal
Care and Use Committee.
Quantiﬁcation of infectious virus. At the indicated day postinfection, mice were euthanized via isoﬂurane overdose, and lung tissue was collected in Omni-Bead Ruptor tubes ﬁlled with 1% FBS–Hanks’
balanced salt solution (HBSS). Tissue was homogenized in an Omni Bead Ruptor 24 instrument (5.15 ms,
15 s). To perform plaque assays, 10-fold dilutions of the viral supernatant in serum-free DMEM (catalog
number 45000-304; VWR) were overlaid onto VeroE6-TMPRSS2-hACE2 cells monolayers and adsorbed
for 1 h at 37°C. After adsorption, 0.5% immunodiffusion agarose in 2 DMEM supplemented with 5%
FBS (Atlanta Biologics) and 1 sodium bicarbonate was overlaid, and cultures were incubated for 48 h
at 37°C. Agarose plugs were removed, cells were ﬁxed with 4% PBS-buffered paraformaldehyde (PFA)
for 15 min at room temperature, and plaques were visualized using crystal violet staining (20% methanol
in double-distilled water [ddH2O]).
Quantitative reverse transcription-PCR of lung tissues. At the indicated day postinfection, mice
were euthanized with an isoﬂurane overdose, and one lobe of lung tissue was collected in an Omni
Bead Ruptor tube ﬁlled with Tri reagent (catalog number R2050-1-200; Zymo). Tissue was homogenized
using an Omni Bead Ruptor 24 instrument (5.15 ms, 15 s) and then centrifuged to remove debris. RNA
was extracted using a Direct-zol RNA miniprep kit (catalog number R2051; Zymo) and then converted to
cDNA using a high-capacity reverse transcriptase cDNA kit (catalog number 4368813; Thermo). RNA levels were quantiﬁed using the IDT Prime Time gene expression master mix and TaqMan gene expression
primer/probe sets (IDT). All qPCRs were performed in 384-well plates and run on a QuantStudio5 qPCR system. SARS-CoV-2 RNA-dependent RNA polymerase levels were measured as previously described (5). The
following TaqMan primer/probe sets (Thermo Fisher) were used in this study: Gapdh (Mm99999915_g1),
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Ifnl2 (Mm04204155_gH), Iﬁt2 (Mm00492606_m1), Iﬁh1 (Mm00459183_m1), Ifnb1 (Mm00439552_s1), Ifna4
(Mm00833969_s1), Ccl2 (Mm00441242_m1), Ccl5 (Mm01302427_m1), Cxcl10 (Mm99999072_m1), Tnf
(Mm00443258_m1), Il1b (Mm00434228_m1), and Il6 (Mm00446190_m1).
Processing of mouse tissues to single-cell suspensions. At the indicated day postinfection, mice
were anesthetized using isoﬂurane and injected retro-orbitally with CD45:PE (100 m l per mouse, diluted
1:20 in PBS). Mice were allowed to recover for 5 min and then euthanized via an isoﬂurane overdose. One
lobe of lung tissue and spleens were collected from each mouse and placed into 1% FBS–HBSS. Spleens
were mechanically homogenized on a 70-m m cell strainer, and the cell suspension was collected in 10%
FBS–RPMI 1640. The splenocyte suspension was spun down (1,250 rpm for 5 min at 4°C) and lysed in ACK
lysis buffer (Lonza) for 5 min on ice. Splenocytes were washed with 10% FBS–RPMI 1640 and then kept on
ice until ready for downstream applications. Lungs were mechanically disrupted in 6-well plates and then
digested for 30 min at 37°C in a solution of DNase I (2,000 U/ml) (catalog number D4527-500KU; Sigma)
and collagenase (5 mg/ml) (catalog number 11088882001; Sigma) in HBSS. Digestion was stopped with
10% FBS–RPMI 1640, and lungs were pushed through a 70-m m ﬁlter to obtain a single-cell suspension. Cells
were resuspended in 30% Percoll–PBS and centrifuged at 2,000 rpm for 20 min. The top layer of cell debris
was removed, and the cell pellet at the bottom was lysed with ACK lysis buffer for 5 min on ice. Cells were
washed, resuspended in 10% FBS–RPMI 1640, and kept on ice until ready for staining.
Flow cytometry analysis. Single-cell suspensions were spun down and resuspended in anti-CD16/32
(clone 2.4G2; Tonbo) blocking solution for 20 min at 4°C. Cell suspensions were spun down and stained
with Live/Dead Ghost dye stain (Tonbo Biosciences) for 20 min at 4°C. Cells were washed and resuspended
in the indicated surface stain in ﬂuorescence-activated cell sorter (FACS) buffer for 20 min at 4°C. After staining, cells were washed and ﬁxed in 2% PFA–PBS for 20 min at room temperature. Precision count beads
(BioLegend) were added to samples to obtain counts. Samples were run on a BD FACS Symphony A5 system. The following antibodies were used in this study: CD45:PE (clone 30-F11; BioLegend), CD45.2:BV605
(clone 104; BioLegend), CD11b:BUV395 (clone 440c; BD Biosciences), I-A/I-E:AF700 (clone M5/114.15.2;
BioLegend), CD11c:BUV737 (clone N418; BioLegend), CD26:PE-Cy7 (clone H194-112; BioLegend), CD172a:
BV510 (clone P84; BioLegend), XCR1:AF647 (clone Zet; BioLegend), CD64:peridinin chlorophyll protein-Cy5.5
(PerCpCy5.5) (clone X54-5/7.1; BioLegend), F4/80:ﬂuorescein isothiocyanate (FITC) (clone BM8; BioLegend),
H2kb:BUV805 (clone AF6-88.5; BD Biosciences), CD86:PE-Dazzle594 (clone GL1; BioLegend), Live/Dead
Ghost dye:R780 (Tonbo), CD3:allophycocyanin (APC)-Cy7 (clone 145-2C11; BioLegend), CD19:APC-Cy7
(clone 1D3; BD Biosciences), NK1.1 (clone PK136; BioLegend), Ly6C:BV785 (clone Hk1.4; BioLegend), Ly6G:
BV650 (clone 1A8; BioLegend), and Siglec-F:BV421 (clone E50-2440; BD Biosciences).
In situ hybridization of lung tissues. One lobe of the lung was harvested from mice at 0 or 4 days
p.i. and ﬁxed with 4% PFA–PBS for a minimum of 3 days. Formalin-ﬁxed parafﬁn-embedded lung tissues
were deparafﬁnized through sequential washes twice each in xylene and 100% ethanol for 5 min.
Tissues were then pretreated with RNAscope hydrogen peroxide for 10 min at room temperature (RT)
and then with RNAscope target retrieval for 5 min at 95°C to 100°C, followed by RNAscope protease plus
for 30 min at 40°C. RNA-ISH was performed using a probe against the S gene of SARS-CoV-2 (V-nCoV2019-S; ACD) using the RNAscope 2.5 HD assay—brown according to the manufacturer’s instructions.
Slides were coverslipped with ProLong gold antifade mountant (Thermo Fisher). Images were acquired
using a Zeiss AxioImager Z2 system with Zeiss software.
Single-cell RNA-Seq analysis. Lungs from mice at 0 or 4 days p.i. were processed to single-cell suspensions as described above. Single-cell suspensions were washed 4 times with PBS and passed through a 70m m ﬁlter. Cell suspensions were counted and captured in droplets using chromium NextGEM single-cell 59
library and gel bead kits on a 10 chromium controller in a BSL-3 cabinet. Ampliﬁcation of cDNA and library
preparation were performed according to the manufacturer’s instructions. Gene expression libraries were
sequenced as paired-end 26-by-91 reads on an Illumina NovaSeq6000 system targeting a depth of 50,000
reads per cell at the Yerkes Genomics Core Laboratory (http://www.yerkes.emory.edu/nhp_genomics_core/).
Analysis was conducted using R (v4) and Seurat (v4). Cell Ranger (v6) was used for demultiplexing, aligning
barcodes, mapping to the genome (mm10), and quantifying UMIs (unique molecular identiﬁers). Filtered
Cell Ranger matrices were processed with the Read10x function in Seurat for preprocessing and cluster analysis. Data were ﬁltered to remove cells with ,200 genes, abnormally high gene counts (feature counts of
.5,000), and .5% mitochondrial genes. After qualify control, there were 9,399 mock cells and 10,982 CoV-2
cells. Principal-component analysis (PCA) and dimensional reduction were conducted on log-normalized and
scaled gene expression data. Clustering was conducted using the FindNeighbors and FindClusters functions,
with resolution parameters between 0.5 and 1.4. Overall, 23 clusters were identiﬁed, and the FindAllMarkers
function was utilized to identify DEGs, from which marker genes for cluster cell annotation was conducted.
After annotating cells, DEGs were determined based on subclusters or experimental groups. Gene set enrichment analysis (GSEA) was conducted using the ranked gene list produced with the Seurat FindMarkers function (comparing CoV-2 samples with mock samples), and Genelists were obtained from MsigDB (hallmarks)
and data reported previously by Wauters et al. (see the supplemental material in reference 34) (macrophage
suppressive and hyperinﬂammatory). GSEA was conducted using Broad (4.0.3) and plotted in R.
Statistical analysis. All experiments in mice were repeated twice with sample sizes of 4 to 6 for ﬂow
cytometry or viral titer experiments and sample sizes of 10 for survival studies. Statistical analysis was performed in GraphPad Prism v8 using the appropriate test for the indicated analysis. The following statistical
tests were used in this study: Student’s t test and unpaired one- or two-way analysis of variance (ANOVA).
scRNA-Seq statistical analysis was performed using the programs described above. Throughout the manuscript, a result was not considered signiﬁcant unless it achieved a P value of ,0.05.
Data availability. Single-cell RNA sequencing data are publicly accessible through the Gene
Expression Omnibus under accession number GSE186360.
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